The anti-leishmanial drug miltefosine causes insulin resistance in skeletal muscle cells in vitro

Diabetologia

Volumn 49, Issue 7, 2006, Pages 1656-1660

  Verma, N K ^a   Dey, C S ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Insulin resistance; Miltefosine; Skeletal muscle; Type 2 diabetes

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANTILEISHMANIAL AGENT; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN; INSULIN RECEPTOR; INSULIN RECEPTOR BETA; INSULIN RECEPTOR SUBSTRATE 1; MILTEFOSINE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; WORTMANNIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; GLUCOSE TRANSPORT; HORMONAL REGULATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; MUSCLE CELL; MYOTUBE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; RISK ASSESSMENT; SIGNAL TRANSDUCTION;

ANIMALS; ANTIPROTOZOAL AGENTS; CELLS, CULTURED; DRUG EVALUATION, PRECLINICAL; GLUCOSE; INSULIN; INSULIN RESISTANCE; MUSCLE FIBERS; MUSCLE FIBERS, SKELETAL; ONCOGENE PROTEIN V-AKT; PHOSPHORYLCHOLINE; RATS;

EID: 33744945002     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-006-0260-1     Document Type: Article

References (10)

1. Verma NK, Dey CS (2004) Possible mechanism of miltefosine mediated death of Leishmania donovani. Antimicrob Agents Chemother 48:3010-3016
2. Terwogt JMM, Mandjes IAM, Sindermann H, Beijnen JH, ten Bokkel Huinink WW (1999) Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer Br J Cancer 79:1158-1161
3. Thakur BB (2003) Breakthrough in the management of visceral leishmaniasis. J Assoc Physicians India 51:649-651
4. Desjeux P (2004) Leishmaniasis. Nat Rev Microbiol 2:692-693
5. Ruiter GA, Zerp SF, Bartelink H, Blitterswijk WJV, Verheij M (2003) Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB/PKB survival pathway. Anti-Cancer Drugs 14:167-173
6. Zhang BB (2002) Insulin signaling and action: glucose, lipids, protein. http://www.endotext.org/diabetes/diabetes4/diabetesfrme4.htm. Last accessed December 2005
7. Khurana A, Dey CS (2002) Involvement of ELK-1 in L6L9 skeletal muscle cell differentiation. FEBS Lett 527:119-124
8. Kumar N, Dey CS (2003) Metformin enhances insulin signaling in insulin-dependent and -independent pathways in insulin resistant muscle cells. Br J Pharmacol 137:329-336
9. Cusi K, Maezono K, Osman A et al (2000) Insulin resistance differentially affects the PI3-kinase and MAP kinase-mediated signaling in human muscle. J Clin Invest 105:311-320
10. Manning AM, Davis R (2003) Targeting JNK for therapeutic benefit: from junk to gold? Nat Rev Drug Discov 2:554-565